{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T22:17:04Z","timestamp":1791584224806,"version":"4.3.4"},"reference-count":10,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2020,7,29]],"date-time":"2020-07-29T00:00:00Z","timestamp":1595980800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,7,29]],"date-time":"2020-07-29T00:00:00Z","timestamp":1595980800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neuroimmune Pharmacol"],"published-print":{"date-parts":[[2020,12]]},"DOI":"10.1007\/s11481-020-09937-4","type":"journal-article","created":{"date-parts":[[2020,7,29]],"date-time":"2020-07-29T02:03:44Z","timestamp":1595988224000},"page":"567-569","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Lipid Profile Alterations during Fingolimod Treatment in Multiple Sclerosis Patients"],"prefix":"10.1007","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3275-9631","authenticated-orcid":false,"given":"Ilkka","family":"Rauma","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heini","family":"Huhtala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Merja","family":"Soilu-H\u00e4nninen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanna","family":"Kuusisto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,7,29]]},"reference":[{"key":"9937_CR1","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1097\/WNF.0b013e3181cbf825","volume":"33","author":"J Chun","year":"2010","unstructured":"Chun J, Hartung H (2010) Mechanism of action of Oral Fingolimod (FTY720) in multiple sclerosis. Clin Neuropharmacol 33:91\u2013101. https:\/\/doi.org\/10.1097\/WNF.0b013e3181cbf825","journal-title":"Clin Neuropharmacol"},{"key":"9937_CR2","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1056\/NEJMoa0907839","volume":"362","author":"JA Cohen","year":"2010","unstructured":"Cohen JA, Barkhof F, Comi G, Hartung H-P, Khatri BO, Montalban X, Pelletier J, Capra R, Gallo P, Izquierdo G, Tiel-Wilck K, de Vera A, Jin J, Stites T, Wu S, Aradhye S, Kappos L, TRANSFORMS Study Group (2010) Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N Engl J Med 362:402\u2013415. https:\/\/doi.org\/10.1056\/NEJMoa0907839","journal-title":"N Engl J Med"},{"key":"9937_CR3","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1093\/clinchem\/18.6.499","volume":"18","author":"W Friedewald","year":"1972","unstructured":"Friedewald W, Levy R, Fredrickson D (1972) Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 18:499\u2013502","journal-title":"Clin Chem"},{"key":"9937_CR4","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1056\/NEJMoa0909494","volume":"362","author":"L Kappos","year":"2010","unstructured":"Kappos L, Radue E-W, O\u2019Connor P, Polman C, Hohlfeld R, Calabresi P, Selmaj K, Agoropoulou C, Leyk M, Zhang-Auberson L, Burtin P (2010) A placebo-controlled trial of Oral Fingolimod in relapsing multiple sclerosis. N Engl J Med 362:387\u2013401. https:\/\/doi.org\/10.1056\/NEJMoa0909494","journal-title":"N Engl J Med"},{"key":"9937_CR5","doi-asserted-by":"publisher","first-page":"2392","DOI":"10.1161\/ATVBAHA.107.149476","volume":"27","author":"R Klingenberg","year":"2007","unstructured":"Klingenberg R, Nofer JR, Rudling M, Bea F, Blessing E, Preusch M, Grone HJ, Katus HA, Hansson GK, Dengler TJ (2007) Sphingosine-1-phosphate analogue FTY720 causes lymphocyte redistribution and hypercholesterolemia in ApoE-deficient mice. Arterioscler Thromb Vasc Biol 27:2392\u20132399. https:\/\/doi.org\/10.1161\/ATVBAHA.107.149476","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"9937_CR6","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1111\/ane.13145","volume":"140","author":"SM Laakso","year":"2019","unstructured":"Laakso SM, Viitala M, Kuusisto H, Sarasoja T, Hartikainen P, Atula S, Tienari PJ, Soilu-H\u00e4nninen M (2019) Multiple sclerosis in Finland 2018\u2014data from the national register. Acta Neurol Scand 140:303\u2013311. https:\/\/doi.org\/10.1111\/ane.13145","journal-title":"Acta Neurol Scand"},{"key":"9937_CR7","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1038\/nature02284","volume":"427","author":"M Matloubian","year":"2004","unstructured":"Matloubian M, Lo CG, Cinamon G, Lesneski MJ, Xu Y, Brinkmann V, Allende ML, Proia RL, Cyster JG (2004) Lymphocyte egress from thymus and peripheral lymphoid organs is dependent on S1P receptor 1. Nature 427:355\u2013360. https:\/\/doi.org\/10.1038\/nature02284","journal-title":"Nature"},{"key":"9937_CR8","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1016\/j.tcm.2005.08.005","volume":"15","author":"J-R Nofer","year":"2005","unstructured":"Nofer J-R, Assmann G (2005) Atheroprotective effects of high-density lipoprotein-associated Lysosphingolipids. Trends Cardiovasc Med 15:265\u2013271. https:\/\/doi.org\/10.1016\/j.tcm.2005.08.005","journal-title":"Trends Cardiovasc Med"},{"key":"9937_CR9","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1161\/CIRCULATIONAHA.106.641407","volume":"115","author":"J-R Nofer","year":"2007","unstructured":"Nofer J-R, Bot M, Brodde M, Taylor PJ, Salm P, Brinkmann V, van Berkel T, Assmann G, Biessen EAL (2007) FTY720, a synthetic sphingosine 1 phosphate analogue, inhibits development of atherosclerosis in low-density lipoprotein receptor-deficient mice. Circulation 115:501\u2013508. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.106.641407","journal-title":"Circulation"},{"key":"9937_CR10","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.vph.2012.03.003","volume":"57","author":"F Poti","year":"2012","unstructured":"Poti F, Costa S, Bergonzini V, Galletti M, Pignatti E, Weber C, Simoni M, Nofer J-R (2012) Effect of sphingosine 1-phosphate (S1P) receptor agonists FTY720 and CYM5442 on atherosclerosis development in LDL receptor deficient (LDL-R\u2212\/\u2212) mice. Vasc Pharmacol 57:56\u201364. https:\/\/doi.org\/10.1016\/j.vph.2012.03.003","journal-title":"Vasc Pharmacol"}],"container-title":["Journal of Neuroimmune Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11481-020-09937-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11481-020-09937-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11481-020-09937-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,28]],"date-time":"2021-07-28T19:26:11Z","timestamp":1627500371000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11481-020-09937-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7,29]]},"references-count":10,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["9937"],"URL":"https:\/\/doi.org\/10.1007\/s11481-020-09937-4","relation":{},"ISSN":["1557-1890","1557-1904"],"issn-type":[{"value":"1557-1890","type":"print"},{"value":"1557-1904","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,7,29]]},"assertion":[{"value":"16 May 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 June 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 July 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"The authors declared the following potential conflicts of interest with respect to the research, authorship, and\/or publication of this article. IR has received reimbursement of travel expenses (Novartis, Sanofi Genzyme, Teva). HH has no conflicts of interest to declare. MS-H has received honoraria for lectures (Biogen, Merck, Novartis, Roche, Sanofi Genzyme, Teva), reimbursement of congress expenses (Biogen, Merck, Roche, Sanofi Genzyme, Teva), and has served on scientific advisory boards (Biogen, Merck, Novartis, Roche, Sanofi Genzyme, Teva). HK has received honoraria for lectures\/consultations (Biogen, Merck, Novartis, Roche, Sanofi Genzyme, Teva), reimbursement of congress expenses (Merck, Sanofi Genzyme, Teva, Zambon), and has served on scientific advisory boards (Biogen, Merck, Novartis, Roche, Sanofi Genzyme, Teva).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This is an observational study. According to local guidelines, ethics approval is not required.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publications"}}]}}